Literature DB >> 6699021

The trend of acquired immunity with live poliovirus vaccine and the effect of revaccination: follow-up of vaccinees for ten years.

O Nishio, Y Ishihara, K Sakae, Y Nonomura, A Kuno, S Yasukawa, H Inoue, K Miyamura, R Kono.   

Abstract

The persistence of neutralizing antibody (NA) against three types of poliovirus acquired after two doses of trivalent live attenuated poliovirus vaccine (LPV) has been followed up for ten years in individual vaccinees. Sixty-seven children were bled once a year over a five year period following the primary vaccination. More than 80% of them retained NA against all three types of poliovirus. Thirty-two individuals whose NA titres were 1:16 or over for types 1 and 2 and 1:4 or over for type 3 at the fifth year were further followed up for a further five years and it was shown that during this period some of them had a naturally-acquired antibody rise, mostly against type 3 virus. At the sixth to eighth year after the primary vaccination, one further dose of the trivalent vaccine was administered to the children whose NA titres were down to 1:8 or less and the effect of booster vaccination on NA was followed. Other subjects were revaccinated with LPV and their fecal excretion of the vaccine virus was investigated. The results showed that a decrease in serum antibody level could be a good indicator of the local resistance of the alimentary tract and that reinfection could occur if serum NA had decreased to 1:8 or less, which allowed a virus excretion in the stools.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6699021     DOI: 10.1016/s0092-1157(84)80015-3

Source DB:  PubMed          Journal:  J Biol Stand        ISSN: 0092-1157


  13 in total

1.  Immunity to poliovirus serotypes in children population of selected communities in South-west, Nigeria.

Authors:  Johnson Adekunle Adeniji; Folakemi Abiodun Osundare; Olubusuyi Moses Adewumi; Anyebe Bernard Onoja; Ademola Hezekiah Fagbami
Journal:  Afr J Infect Dis       Date:  2015

2.  Toward a poliovirus-based simian immunodeficiency virus vaccine: correlation between genetic stability and immunogenicity.

Authors:  S Tang; R van Rij; D Silvera; R Andino
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

3.  Successes and shortcomings of polio eradication: a transmission modeling analysis.

Authors:  Bryan T Mayer; Joseph N S Eisenberg; Christopher J Henry; M Gabriela M Gomes; Edward L Ionides; James S Koopman
Journal:  Am J Epidemiol       Date:  2013-04-16       Impact factor: 4.897

4.  Achieving high immunogenicity against poliovirus with fractional doses of inactivated poliovirus vaccine in Ecuador-results from a cross-sectional serological survey.

Authors:  Gabriel Trueba; Vishali Jeyaseelan; Lazaro Lopez; Bernardo A Mainou; Yiting Zhang; Alvaro Whittembury; Alfredo Jose Olmedo Valarezo; Gonzalo Baquero; Rosa Romero de Aguinaga; Lucia Jeannete Zurita Salinas; Maria Gabriela Santacruz Mancheno; Diana Elizabeth Medina Chacho; Emmanuelle Quentin; Ana Elena Chevez; Gloria Rey-Benito; Ondrej Mach
Journal:  Lancet Reg Health Am       Date:  2022-07

5.  Poliovirus vaccine vectors elicit antigen-specific cytotoxic T cells and protect mice against lethal challenge with malignant melanoma cells expressing a model antigen.

Authors:  S Mandl; L J Sigal; K L Rock; R Andino
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

Review 6.  Interrupting the transmission of wild polioviruses with vaccines: immunological considerations.

Authors:  Y Ghendon; S E Robertson
Journal:  Bull World Health Organ       Date:  1994       Impact factor: 9.408

7.  Immunity status of adults and children against poliomyelitis virus type 1 strains CHAT and Sabin (LSc-2ab) in Germany.

Authors:  Maren Eggers; Elena Terletskaia-Ladwig; Holger F Rabenau; Hans W Doerr; Sabine Diedrich; Gisela Enders; Martin Enders
Journal:  BMC Infect Dis       Date:  2010-12-09       Impact factor: 3.090

8.  Boosting of Mucosal Immunity After Fractional-Dose Inactivated Poliovirus Vaccine.

Authors:  Deepa Gamage; Ondrej Mach; Paba Palihawadana; Yiting Zhang; William C Weldon; M Steven Oberste; Sunethra Gunasena; Roland W Sutter
Journal:  J Infect Dis       Date:  2018-11-05       Impact factor: 7.759

9.  Quantifying the impact of expanded age group campaigns for polio eradication.

Authors:  Bradley G Wagner; Matthew R Behrend; Daniel J Klein; Alexander M Upfill-Brown; Philip A Eckhoff; Hao Hu
Journal:  PLoS One       Date:  2014-12-01       Impact factor: 3.240

10.  Exploring the relationship between polio type 2 serum neutralizing antibodies and intestinal immunity using data from two randomized controlled trials of new bOPV-IPV immunization schedules.

Authors:  Ananda S Bandyopadhyay; Edwin J Asturias; Miguel O'Ryan; M Steven Oberste; William Weldon; Ralf Clemens; Ricardo Rüttimann; John F Modlin; Chris Gast
Journal:  Vaccine       Date:  2017-11-14       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.